Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
about
Progress and perspectives on targeting nanoparticles for brain drug delivery.Advancing Cardiovascular, Neurovascular, and Renal Magnetic Resonance Imaging in Small Rodents Using Cryogenic Radiofrequency Coil TechnologyVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationTargeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.Contemporary murine models in preclinical astrocytoma drug developmentTargeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer CellsA chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizerStrategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization.The Application of Heptamethine Cyanine Dye DZ-1 and Indocyanine Green for Imaging and Targeting in Xenograft Models of Hepatocellular CarcinomaThe cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells.The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomasZoledronic acid overcomes chemoresistance and immunosuppression of malignant mesotheliomaBreast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team upMulti-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma.CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.Absence of human cytomegalovirus infection in childhood brain tumors.CNS Anticancer Drug Discovery and Development Conference White Paper.Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor modelActive efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells.Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaPharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro.Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells.Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases.A complete compilation of matrix metalloproteinase expression in human malignant gliomas.Which drug or drug delivery system can change clinical practice for brain tumor therapy?Epidermal growth factor receptor as a therapeutic target in glioblastoma.Targeted delivery of nano-therapeutics for major disorders of the central nervous system.Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues.
P2860
Q26740580-EC236BED-DE83-4C2E-AB98-F6847FC5257BQ26776191-363217A8-E994-43E2-AF96-19DF583672CEQ26781833-4DE1A3AF-E40A-45F3-BD5C-3B492B1E8399Q27010580-28BD0F95-EA0D-44BB-8145-1DE09754EC9EQ27026937-CC0B7006-EEAC-4EF4-8109-29C6B2641F72Q27316967-65C8D36C-2B5D-4099-8C50-EC2AE1C5ED5CQ28547142-E311C049-A657-45A9-AFA0-BB65919E2436Q28822232-E7198A55-21B8-4138-9B06-E120B0A22D58Q30366921-866A9D30-0D4D-41E6-9019-136504C4D871Q30543786-F13EC011-D19A-4AEA-9D9B-A85D3BAEC5EEQ33839211-EE9AF8C3-AE75-46CC-A755-E16C20613290Q34018635-F0169DAF-6813-4AC0-A3DE-22BA1A83077DQ34097238-DA6DBD69-600E-4F0F-9634-9C2433ECCFC9Q35171890-F0816B6B-E061-4690-AF34-AB4A84EF268DQ35176037-B8CC3A0F-EFAA-467A-967F-56BD8EF965D8Q35720625-7852E4D9-5141-446C-B834-B74F7AC8FCA3Q35849699-003173C3-7709-404A-8740-2BBACCCF87D8Q35911313-122A47C5-B808-42C4-AB5F-5C9E4BA7F954Q35913169-C10D8414-60B5-4C66-93AC-69E287898631Q36057137-8300A6B5-6B5E-4F02-8435-18B92009A5E0Q36089590-8BDB547B-B848-4F3A-B546-6C703569987BQ36105340-4A72A73F-BCD4-4C36-A978-C419FA121069Q36107368-208CCB9D-57D0-4F9E-8300-4F92A0875799Q36186193-9F74AFFB-3E86-4AEB-A791-59004310D9B9Q36312901-BE806D46-A6A8-4C7D-8B75-2609E874D58CQ36497633-3AA4C82C-ED2B-482C-9AD5-37935C224CE9Q36717122-844B367A-F397-4EC1-9D5E-AC12E54F749AQ36789564-D9EDCFF8-2BBC-422A-B58D-36FB51AAEAD5Q36887663-810B4C15-17A7-4425-ADC8-020F099FD41BQ37331814-E0B50E8A-84DA-4AAA-AFC1-363C03FCCF80Q37388728-EA87E8EA-D3E8-4FD7-88ED-D16DEB9247CFQ37554942-DBA19BB6-E4AA-46FD-8327-BA896EF4084AQ37668774-9DFF280E-4DCD-46E7-BBE9-803B926A5A53Q37688267-7018F6C0-2A22-4999-9289-F4948787DF52Q37890058-D6E78FFB-A333-4941-9A6B-77F9CA0F42D5Q38009800-B1836D8A-6367-4510-822A-989AE44B1EE1Q38090394-9F23074C-E88C-424E-B8E6-AD509AC6D822Q38098098-7F558BA6-F27B-4FF5-966C-CA2B290F461DQ38116765-ACD7DC6A-E51A-4A6E-BA82-4ACF581EA705Q38200490-B2C99F86-45D5-49D4-83AA-5CD500DC01B2
P2860
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Delivery of molecularly target ...... a disease of the whole brain.
@en
Delivery of molecularly target ...... a disease of the whole brain.
@nl
type
label
Delivery of molecularly target ...... a disease of the whole brain.
@en
Delivery of molecularly target ...... a disease of the whole brain.
@nl
prefLabel
Delivery of molecularly target ...... a disease of the whole brain.
@en
Delivery of molecularly target ...... a disease of the whole brain.
@nl
P2093
P2860
P1476
Delivery of molecularly target ...... a disease of the whole brain.
@en
P2093
John R Ohlfest
Rajneet Oberoi
Ramola Sane
Sagar Agarwal
William F Elmquist
P2860
P356
10.1017/S1462399411001888
P577
2011-05-13T00:00:00Z